681128-39-2 Usage
Description
(3,3-Difluorocyclobutyl)methanol is an organic compound characterized by its cyclobutyl ring structure with two fluorine atoms at the 3,3-positions and a hydroxyl group attached to the carbon at the 1-position. This unique molecular structure endows it with specific properties that make it useful in various applications, particularly in the pharmaceutical industry.
Uses
Used in Pharmaceutical Industry:
(3,3-Difluorocyclobutyl)methanol is used as an intermediate for the synthesis of diaminoalkane aspartic protease inhibitors. These inhibitors are essential in the development of drugs targeting various diseases, including viral infections and cancer, by disrupting the activity of specific proteases involved in the disease progression.
The application of (3,3-Difluorocyclobutyl)methanol in the pharmaceutical industry is primarily due to its ability to serve as a key building block in the creation of potent and selective protease inhibitors. These inhibitors can play a crucial role in the treatment of diseases by modulating the activity of proteases, which are often overexpressed or dysregulated in pathological conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 681128-39-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,8,1,1,2 and 8 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 681128-39:
(8*6)+(7*8)+(6*1)+(5*1)+(4*2)+(3*8)+(2*3)+(1*9)=162
162 % 10 = 2
So 681128-39-2 is a valid CAS Registry Number.
InChI:InChI=1/C5H8F2O/c6-5(7)1-4(2-5)3-8/h4,8H,1-3H2
681128-39-2Relevant articles and documents
Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases
-
, (2012/05/21)
The present invention relates to novel compounds of formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compounds, processes for making said compounds, and their use as medicaments for treatment and/or prevention of Aβ-related diseases.
